Human Regenerative Technologies LLC – Trademark Portfolio
Entity Type: 16
Human Regenerative Technologies LLC holds 27 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 27 filings in this category. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include HRT, PLACENTAL TISSUE MATRIX THERAPY, COMPLETE PLACENTAL TISSUE MATRIX, and THE ORIGINAL PLACENTAL TISSUE MATRIX. The owner is based in EL SEGUNDO, CA.
2255 CAMPUS DRIVE
EL SEGUNDO, CA 90245
Showing of trademarks Trademarks
Trademark Classifications
Human Regenerative Technologies LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Human Regenerative Technologies LLC have?
Human Regenerative Technologies LLC has 27 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 22 cancelled.
What trademark classes does Human Regenerative Technologies LLC file in?
Human Regenerative Technologies LLC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Human Regenerative Technologies LLC's most well-known trademarks?
Human Regenerative Technologies LLC's registered trademark portfolio includes well-known marks such as HRT, PLACENTAL TISSUE MATRIX THERAPY, COMPLETE PLACENTAL TISSUE MATRIX, and THE ORIGINAL PLACENTAL TISSUE MATRIX. These are among 4 currently registered trademarks in the portfolio.
What is Human Regenerative Technologies LLC's trademark registration success rate?
Human Regenerative Technologies LLC has a 15% trademark registration rate, with 4 out of 26 resolved applications resulting in successful registration. Currently, 1 application is pending review.